Sofie CO.

Sofie CO., doing business as IBA Molecular, manufactures and supplies FDA-approved positron emission tomography radiopharmaceuticals to the federal government as a prime contractor, operating as a subsidiary of Sofie Biosciences, Inc. The company competes full-and-open across its prime footprint with no recurring set-aside posture, though it holds total small business set-aside IDIQs with specific VA Veterans Integrated Service Networks.

Sofie CO. is a for-profit manufacturer headquartered in Sterling, Virginia, with manufacturing and distribution capabilities supporting federal healthcare agencies. The vendor's concrete capability is radiopharmaceutical manufacturing and supply—specifically FDA-approved positron emission tomography imaging agents and diagnostic radiopharmaceuticals for oncology, prostate cancer, Alzheimer's disease, and neuroendocrine tumor imaging. The company holds current U.S. Nuclear Regulatory Commission and Food and Drug Administration licenses and manufactures products including PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, F-18 fluorodeoxyglucose for general oncology applications, and specialized gallium-68 and copper-64 radiopharmaceuticals. Representative prime awards include a $5.864 million total small business set-aside IDIQ with VA VISN 15 (June 2024) for PYLARIFY F-18 DCFPYL supply through May 2029; a $6.281 million purchase order from VA VISN 19 (October 2023) for PET/CT radiopharmaceuticals through September 2028; and a $1.5 million Defense Health Agency master blanket purchase agreement (February 2024) for pharmaceutical supplies and radiopharmaceuticals through February 2029.

Customer concentration heavily favors VA regional networks and the Defense Health Agency. The top five customers by potential value—VA VISN 2, VA VISN 15, the Defense Health Agency, the Army Medical Command, and VA VISN 10—account for 59% of combined potential value across 457 total awards. VA VISN 2 leads with 46 awards valued at $28.6 million combined potential, followed by VA VISN 15 with 25 awards at $22.5 million. The Defense Health Agency places 72 awards (highest count) valued at $19.3 million. Activity has remained steady at 27–32 awards per year over the past five years, with 12 awards in 2026 year-to-date. Thirteen awards (combined potential value $14 million) reach ultimate completion within the next twenty-four months, presenting recompete exposure across multiple VA networks.

Vehicle position centers on single-award IDIQs and blanket purchase agreements with VA regional networks and the Defense Health Agency. The vendor holds blanket purchase agreements HT001421A0014 (30 task orders, $1.4 million) and HT001424A0002 (21 task orders, $2.1 million), as well as indefinite delivery contracts V652P3841 (17 task orders) and VA244P0998 (6 task orders, $991 thousand). Multiple single-award IDIQs with VA VISNs 2, 4, 15, 16, 17, 19, and 21 facilitate ongoing radiopharmaceutical procurement, with ceiling values ranging from $676 thousand to $6.281 million and performance periods extending through 2027–2031. The Defense Health Agency master BPA and multiple smaller VA agreements form the backbone of task-order placement.

Primary NAICS classification is 325412 (Pharmaceutical Preparation Manufacturing), which covers 295 of 457 awards. Secondary classification under PSC code includes Drugs and Biologicals (200 awards), In Vitro Diagnostic Substances (126 awards), and Medical and Surgical Instruments (40 awards). The vendor also holds 3 federal grant sub-awards as a sub-recipient through Mayo Clinic, supporting clinical development of 68Ga-FAPI-46 PET imaging agents for pancreatic cancer and related oncology applications (awards in February 2024, October 2024, and November 2025).

Sofie CO. is structured as a subsidiary of Sofie Biosciences, Inc., a for-profit manufacturer. The parent company designation and subsidiary relationship enable centralized manufacturing and regulatory compliance across federal deliveries while maintaining Sofie CO. as the distinct federal contracting entity. The vendor's 99% prime-award footprint (454 of 457 awards) reflects direct contractual relationships with federal healthcare customers rather than subcontract work; the 3 sub-awards are grant sub-awards under Mayo Clinic as prime grantee.

Recent invoiced revenue and workforce scale are not stated in the source. Combined potential value across all 457 awards stands at $161.3 million, with $66.9 million (41%) obligated to date, indicating substantial government business embedded in active IDIQs and BPAs across the VA system and Defense Health Agency.